What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Prior cerebrovascular accident (CVA) or transient ischaemic attack (TIA) (n=167). Intervention: Icosapent ethyl. Primary outcome: Patient understanding, confidence, and support needs regarding icosapent ethyl.

What question did this study set out to answer?

The study aims to understand patients' perspectives on their residual cardiovascular disease risk after a cerebrovascular event while using icosapent ethyl.

May 8, 2026European Stroke JournalOpen Access

Abstract Number: Esoc2026a1628 Understanding Residual Risk Reduction From the Patients' Perspective: A Mixed-Methods Survey of Patients Prescribed Icosapent Ethyl for Secondary Prevention in Rural English Primary Care

View Full Paper

Ask AI

Bookmark

Key result

Most patients prescribed icosapent ethyl report limited understanding, with under 25% recognizing elevated triglycerides.

n=167

Key Points

The study aims to understand patients' perspectives on their residual cardiovascular disease risk after a cerebrovascular event while using icosapent ethyl.
An anonymised electronic survey was distributed to patients prescribed icosapent ethyl in primary care.
Quantitative data were collected on knowledge, confidence, and concerns, supplemented by qualitative comments.
Ethical approval was obtained, and descriptive statistics and thematic analysis were employed.
167 patients responded to the survey with a 98.2% consent rate.
Over 50% of respondents felt confident taking the medication, but 55.6% had limited understanding of its mechanism of action.
Qualitative themes revealed a need for better explanations of residual risk and accessible information regarding effectiveness and safety.

Study Design

Type

Cross-Sectional (n=167)

Structured PICO

Population

167 patients with prior CVA or TIA prescribed icosapent ethyl in rural English primary care.

Exposure

Icosapent ethyl (survey of patient understanding, confidence, and support needs)

Outcome

Patients' understanding, confidence, and support needs regarding icosapent ethylpatient reported

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

A significant confidence-comprehension gap exists among rural primary care stroke/TIA patients prescribed icosapent ethyl, highlighting the need for improved patient-centered education.

Cite This Study

Carl Deaney (2026) conducted a cross-sectional in Prior cerebrovascular accident (CVA) or transient ischaemic attack (TIA) (n=167). Icosapent ethyl was evaluated on Patient understanding, confidence, and support needs regarding icosapent ethyl. Among patients prescribed icosapent ethyl for secondary prevention, 55.6% reported limited understanding of its mechanism and <25% correctly identified raised triglycerides as its indication.

synapsesocial.com/papers/69fd7fa1bfa21ec5bbf0827b https://doi.org/10.1093/esj/aakag023.775

View Full Paper

Ask AI

Bookmark

Implication

A significant confidence-comprehension gap exists among rural primary care stroke/TIA patients prescribed icosapent ethyl, highlighting the need for improved patient-centered education.

Abstract Number: Esoc2026a1628 Understanding Residual Risk Reduction From the Patients' Perspective: A Mixed-Methods Survey of Patients Prescribed Icosapent Ethyl for Secondary Prevention in Rural English Primary Care

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Abstract Number: Esoc2026a1628 Understanding Residual Risk Reduction From the Patients' Perspective: A Mixed-Methods Survey of Patients Prescribed Icosapent Ethyl for Secondary Prevention in Rural English Primary Care

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider